Previous 10 | Next 10 |
Esperion's (NASDAQ:ESPR) Q3 2021 earnings beat was helped by sales of its two cholesterol-lowering drugs. The company reported net product revenue in the quarter composed of sales of Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) of $10.9M, up from $4.8M in th...
Esperion Therapeutics (NASDAQ:ESPR): Q3 GAAP EPS of -$2.62 beats by $0.22. Revenue of $14.41M (+276.2% Y/Y) beats by $2.52M. Press Release For further details see: Esperion Therapeutics EPS beats by $0.22, beats on revenue
– Recently Announced Transformative Plan to Align Operational and Expense Structure to the Current Environment and Position for Long-Term Growth – – Unprecedented CLEAR Outcomes Study Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Acc...
ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of three abstracts at the American Heart Association (AHA) Scientific Sessions 2021 taking place on November 13-15, 2021. AHA Scientific Sessions 2021 Bempedoic Acid ...
Esperion Therapeutics (NASDAQ:ESPR) is scheduled to announce Q3 earnings results on Tuesday, November 2nd, before market open. The consensus EPS Estimate is -$2.80 and the consensus Revenue Estimate is $11.89M (+210.4% Y/Y). Last month, Seeking Alpha contributor Biologics argued that "th...
ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Seth H.Z. Fischer as a Class III director, with a term expiring at the 2022 meeting of stockholders. "On behalf of the Esperion team and our directors, I am very pleased to w...
Esperion continues to struggle to get NEXLETOL and NEXLIZET off the launch pad as COVID-19 headwinds disrupt their commercial efforts. The lackluster launch and relentless cash burn has crushed the share price to all-time lows. The cost cutting should help reduce the need for crus...
Esperion Therapeutics (NASDAQ: ESPR) had a day to forget on Monday as its stock lost more than 11% on news that a fresh stack of shares would be coming to the market. Esperion announced Monday morning that it has entered into a private agreement with two holders of its convertib...
Gainers: IceCure Medical (NASDAQ:ICCM) +15%, Kiromic BioPharma KRBP +12%, Eargo (NASDAQ:EAR) +12%, Context Therapeutics (NASDAQ:CNTX) +11%, Xeris Biopharma XERS +11%. Losers: ERYTECH Pharma ERYP -39%, Eyenovia EYEN -37%, Es...
ANN ARBOR, Mich., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a privately negotiated exchange agreement with two co-managed holders (the “Holders”) of its 4.00% Convertible Senior Subordinated Notes due 2025 (the "Notes")....
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...